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Abstract: Metal coordination compounds have an important role in the development of novel drugs. Using the resazurin microtitration
assay we assessed the cytotoxicity and antiviral activity of the ligand 2-(diphenylphosphino)benzaldehyde 1-adamantoylhydrazone
and its Pd(II) and Pt(II) complexes. Cytotoxicity was tested in A549 human lung adenocarcinoma epithelial cells. We observed that
the ligand displayed a more pronounced cytotoxic activity than the platinum-based drug, carboplatin. Morphological evaluation of
A549 cells treated with the ligand by acridine orange and ethidium bromide double staining revealed the presence of signs of apoptosis.
Antiviral activity against poliovirus type 1 was assessed by examination of the cytopathic effect (CPE) in Hep-2 cells. Cells that were
exposed to the 19 µM ligand before infection displayed a maximal significant reduction (by 24.42 ± 1.49%) of the CPE. This was likely
due to the inhibition of virus receptors and prevention of viral adsorption. Treatment with 17 µM Pt(II) complex after viral infection
caused a maximal significant reduction (by 30.52 ± 3.12%) of the CPE, presumably through an effect on viral replication. The results
indicate that the ligand should be viewed as a potential anticancer agent. The ligand and the Pt(II) complex show promising results for
further investigation of antiviral activity.
Key words: Cytotoxicity, antiviral activity, 2-(diphenylphosphino)benzaldehyde hydrazone ligands, cancer cell lines, apoptosis

1. Introduction
The clinical use of metal coordination compounds has
improved considerably in recent years in clinical therapy.
Platinum-based drugs (cisplatin, carboplatin, and
oxaliplatin) have a wide use in the treatment of human
malignancies, such as ovarian, testicular, head and neck,
and lung cancers. Considerable effort has been devoted
to the development of new anticancer metal coordination
compounds that impede the development of resistance and
produce fewer side effects during chemotherapy (Frezza et
al., 2010).
Uncovering the anticancer properties of phosphines
has led to the development and biological evaluation of
numerous metal complexes with phosphine ligands (Starosta
et al., 2011; Galassi et al., 2012; Milenković et al., 2013a,
2013b). Metal complexes with 2-(diphenylphosphino)
benzaldehyde (dpba) hydrazone ligands also have
improved cytotoxic activity (Malešević et al, 2006). In
our previous work we investigated the biological activity
of the novel synthesized ligand 2-(diphenylphosphino)
* Correspondence: verasimic@gmail.com

benzaldehyde 1-adamantoylhydrazone and its Pd(II) and
Pt(II) complexes (Figure 1) in human larynx carcinoma
Hep-2 cells and healthy human lung MRC-5 cells (Đorđević
et al., 2014). The antiviral activities of Pt(II) and Pd(II)
complexes with 2-(diphenylphosphino)benzaldehyde
1-adamantoylhydrazone ligand have not been studied.
Several studies have shown that palladium complexes
have cytotoxic activities similar to standard platinumbased drugs (Gao et al., 2010). Some palladium complexes
have better growth-inhibition effects on human nonsmallcell lung cancer in vitro than cisplatin (Ulukaya et al.,
2011).
Ligand 2-(diphenylphosphino)benzaldehyde 1-adamantoylhydrazone and its Pd(II) and Pt(II) complexes
contain an adamantyl group, which changes the therapeutic
profile of the pharmacologically active molecules (Liu
et al., 2011). Compounds with the adamantyl group are
widely used for prophylaxis and treatment of influenza
infections (Monto, 2003) and also possess antiviral
potency against viruses of the family Picornaviridae (De
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Figure 1. Chemical structures of a) ligand and b) palladium(II) and platinum(II)
complexes (M = Pd, Pt).

Palma et al., 2008). Poliovirus, a member of the genus
Enterovirus (family Picornaviridae), is a causative agent
of paralytic poliomyelitis. The Hep-2 cell line is a suitable
host cell model with an elevated sensitivity to poliovirus
infection. Hep-2 cells provide a high yield of poliovirus
and exhibit a visible and reliable level of cytopathic effect
(CPE) (Johnston and Siegel, 1990; WHO, 1997).
In this study we examined the cytotoxicity of
ligand 2-(diphenylphosphino)benzaldehyde 1-adamantoylhydrazone and its Pt(II) and Pd(II) complexes
in A549 human lung adenocarcinoma cells, and their
antiviral activity against poliovirus type 1 in Hep-2 cells
using the resazurin microtitration assay (UptiBlue assay).
2. Materials and methods
2.1. Reagents and chemicals
Minimal essential medium (MEM, GIBCO), penicillinstreptomycin (Pen Strep, 10,000 U/mL penicillin, 10,000
µg/mL streptomycin, GIBCO), nonessential amino acids
(MEM NEAA, GIBCO), L-glutamine (2 mM, GIBCO),
fetal bovine serum (FBS, GIBCO), nutrient medium
(MEM, 1% Pen Strep, 1% MEM NEAA, 1% L-glutamine,
supplemented with FBS), trypsin-EDTA (0.05%, GIBCO),
UptiBlue (Uptima, Interchim), acridine orange (10 mg/mL,
Sigma), ethidium bromide (10 mg/mL, Sigma), Dulbecco’s
phosphate-buffered saline (DPBS, GIBCO), dimethyl
sulfoxide (DMSO, Sigma-Aldrich), cisplatin (0.5 mg/mL,
Cisplatin, Medac), carboplatin (10 mg/mL, CarboplatinTeva, Teva), oxaliplatin (5 mg/mL, Eloxatin, SanofiAventis), interferon α-2a (3 × 106 IU/0.5 mL, Roferon-A,
Roche), poliovirus reference standard (2nd International
Reference Reagent 2004 for Live Attenuated Poliovirus
(Sabin), National Institute for Biological Standards and
Control, code: 02/306), and antipoliovirus sera (3rd
International Standard Anti-Poliovirus Serum Types 1,
2, and 3, National Institute for Biological Standards and
Control, code: 82/585) were used.
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2.2. Test compounds
2-(Diphenylphosphino)benzaldehyde 1-adamantoylhydrazone (HL) (43.1 mM, referred to as compound ‘1’);
Pd(II) complex with 2-(diphenylphosphino)benzaldehyde
1-adamantoylhydrazone, [Pd(L)Cl], (34.3 mM, compound
‘2’); and Pt(II) complex with 2-(diphenylphosphino)
benzaldehyde
1-adamantoylhyd-razone,
[Pt(L)Cl],
(19.8 mM, compound ‘3’) were used at the indicated
concentrations.
2.3. Virus
As a starting virus suspension, we used the poliovirus
reference standard, which contains a mixture of poliovirus
types 1, 2, and 3. Antipoliovirus sera types 2 and 3 were
added to the poliovirus reference standard. Poliovirus
types 2 and 3 were neutralized at 37 °C for 3 h. After
neutralization of poliovirus types 2 and 3, the content of
poliovirus type 1 was determined by the microtitration
assay in Hep-2 cell culture, using the Kärber formula. The
results were expressed as a tissue culture infection dose
per milliliter (TCID50/mL) (WHO, 1997). The stock virus
suspension was aliquoted and stored at –20 °C until use.
Dilution of the virus suspension was prepared in nutrient
medium supplemented with 2% FBS.
2.4. Cell cultures
A549 human lung adenocarcinoma epithelial cells and
Hep-2 human larynx carcinoma cells were cultivated in a
nutrient medium supplemented with 5%–10% FBS at 37
°C and 5% CO2. The confluent monolayer was trypsinized
with 0.05% trypsin-EDTA. The cells were resuspended
in a nutrient medium supplemented with 10% FBS and
placed into cell culture 96-well microtiter plates (Nunc), at
a concentration of 1 × 105 cells/mL. The microtiter plates
were incubated for 24 h at 37 °C and 5% CO2 humidified
air. The quality of the cell monolayer was confirmed with
an inverted microscope (Freshney, 2005).
2.5. Cytotoxicity assay in A549 cells
The cytotoxic potential of test compounds 1, 2, and 3 was
assayed in the A549 lung adenocarcinoma epithelial cell
line, using UptiBlue (Vega-Avila and Pugsley, 2011).
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The A549 cell line is chosen for the cytotoxicity
examination due to a high potential for resistance
development to cisplatin (Cetintas et al., 2012). The
cytotoxic drugs cisplatin, carboplatin, and oxaliplatin
served as positive controls. Two-fold serial dilutions
were prepared in nutrient medium supplemented with
10% FBS, starting from 336.5 µM, 268 µM, and 155.2 µM
for compounds 1, 2, and 3, respectively, and from 416
µM, 672 µM, and 628 µM for cisplatin, carboplatin, and
oxaliplatin, respectively. Diluted compounds were added
to microtiter plates with an A549 cell monolayer. The
cells were incubated for 48 h at 37 °C and 5% CO2. The
following controls were included: a cell control consisting
of untreated cells; a control of the solvent, which consisted
of cells in two-fold serial dilutions of DMSO, starting
from 0.78%, that corresponded to the test compounds;
and nutrient medium supplemented with 10% FBS, which
served as the blank. Changes in cell morphology were
observed through an inverted phase contrast microscope.
After the treatment, the plates were subjected to the
UptiBlue assay.
UptiBlue is resazurin-based viable stain and it is
used as an oxidation-reduction indicator that undergoes
colorimetric change in response to cellular metabolic
reduction. The amount of resazurin conversion into
resorufin is linearly related to the number of viable cells
and it can be measured spectrophotometrically.
In the UptiBlue assay the medium was removed after
the respective treatments. After the cell monolayers were
rinsed with DPBS, 10% of UptiBlue solution diluted in
nutrient medium supplemented with 10% FBS was added.
The plates were incubated for an additional 3 h at 37 °C
and 5% CO2. Absorbance was recorded using a Thermo
Labsystems Multiscan Acsent plate reader at 540 nm and
600 nm.
The percentages of cell survival were calculated
according to the instructions for UptiBlue. IC50 values in
the cytotoxicity assay were defined as the concentrations
of the compounds that inhibited 50% of cell growth as
compared to the positive growth control. IC50 values were
determined from the cell growth diagrams.
2.6. Acridine orange and ethidium bromide double
staining
Morphological analysis of apoptosis by double staining
with acridine orange and ethidium bromide (AO/EB)
was used to distinguish live nonapoptotic, apoptotic,
and necrotic cells, based on membrane integrity and
chromatin condensation (Squier and Cohen, 2001).
AO is taken up by both viable and nonviable cells and
emits green fluorescence if bound to nuclear DNA and
red fluorescence if bound to RNA, mitochondrial DNA,
or secretion granules (lysosomes). Ethidium bromide
permeates only nonviable cells with damaged membranes

and emits red fluorescence by intercalation into DNA.
The A549 cells were treated with the IC50 concentration
of ligand for 48 h. After the treatment, A549 cells were
washed with DPBS and trypsinized. The cells were stained
with 2 µL of AO/EB solution (100 µg/mL AO and 100 µg/
mL EB) and observed under a fluorescence microscope
(Leica) at 400× magnification within 30 min before
the fluorescence color started to fade. According to the
fluorescence emission and the morphological aspect of
chromatin condensation of stained nuclei, the cells were
distinguished as described by Baskić et al. (2006).
2.7. Antiviral activity against poliovirus type 1 in Hep-2
cells
Antiviral activity was expressed as the ability of the agents
to reduce poliovirus type 1 induction of CPE in Hep-2 cells
as observed by the UptiBlue assay. The antiviral activity
assay included two types of treatments with the ligand
and the Pd(II) and Pt(II) complexes that are referred to
as preinfection and postinfection treatments. Two-fold
serial dilutions of compounds 1, 2, and 3 were prepared
in nutrient medium supplemented with 2% FBS, starting
from 19 µM, 8.24 µM, and 17 µM, respectively, based on
the reported cytotoxicity results obtained previously in the
Hep-2 cell line (Đorđević et al., 2014). Cells treated with
interferon α-2a served as a positive control of antiviral
activity (Cantell and Strander, 1966). It was previously
established that interferon α-2a at concentrations of up
to 1000 IU/mL are not cytotoxic. The highest applied
concentration of interferon α-2a was 400 IU/mL. The test
included a cell control (untreated cells), a solvent control
(cells with two-fold serial dilutions of DMSO, starting from
0.1%, which corresponded to the test compounds), and a
control of viral infectivity (cells incubated with the virus
suspension); nutrient medium supplemented with 2% FBS
provided the blank. At the end of the antiviral assay, 100%
CPE was confirmed in the control for viral infectivity
with an inverted phase contrast microscope. After the
treatment, the plates were subjected to the UptiBlue assay.
EC50 values in the antiviral activity assay were defined
as the concentrations of the compounds that inhibited 50%
viral activity as compared to the positive growth control.
EC50 values were read from the viral growth inhibition
diagrams (CPE reduction diagrams). Antiviral activity
was quantitatively expressed as the therapeutic index (TI),
defined as the relative effectiveness of the test compound
in inhibiting viral activity as compared to its effectiveness
in inducing cell death (IC50 / EC50) (FDA, 2006). When it
was not possible to calculate the TI values, the results were
expressed as percentages of CPE reduction.
2.7.1. Preinfection treatment assay
Hep-2 cell monolayers incubated with test compounds 1, 2,
and 3 and the corresponding controls were maintained for
5 h at 37 °C and 5% CO2. After incubation, the compounds
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3. Results
3.1. Cytotoxicity in A549 cells
The results of the cytotoxicity in A549 cells showed that
cisplatin and oxaliplatin have similar cytotoxic activities,
with IC50 values at concentrations of 40 ± 1.4 µM and 42.6
± 2.5 µM, respectively (Figure 2A). Carboplatin showed a
lower cytotoxic capacity for inducing cell growth inhibition
(IC50 = 256.1 ± 14.0 µM). The obtained IC50 value for the

ligand was 165.9 ± 17.6 µM. Pd(II) and Pt(II) complexes
did not exhibit cytotoxic activities in A549 cells (Figure
2B).
3.2. Morphological changes in A549 cells
The morphological changes in A549 cells were observed
using inverted phase contrast (Olympus) and fluorescence
(Leica) microscopes. After 48 h of incubation, most of the
control A549 cells exhibited typical cell morphology: the
cells were polygonal or slightly prolate and adherent to the
tissue culture dishes (Figures 3A and 3B). Examination
of the morphology of A549 cells treated with ligand at a
concentration of 168.3 µM after 24 h (Figures 3C and 3D)
and 48 h (Figures 3E and 3F) revealed different degrees
of morphological changes, including loss of cell adhesion,
membrane shrinkage, membrane blebbing, condensation
of the cytoplasm and vacuolization, nuclear fragmentation,
formation of apoptotic bodies and echinoid spikes, and
cell fragmentation.
After AO/EB double staining, the control A549 cells
showed typical morphology of live cells with bright
green uniform nuclei (Figures 4A and 4B). After 48 h
of treatment, most of the cells were in the early stage of
Cytotoxic drugs
apoptosis. The early apoptotic cells showed green nuclei
Cisplatin
Carboplatin
Oxaliplatin
and perinuclear
chromatin
condensation
was visible as
120
bright green patches (Figure 4C). Only a small fraction of
the100
cell population was in the late apoptotic stage. The late
apoptotic cells were identified by orange to red nuclei with
condensed
or fragmented chromatin (as a consequence
80
of EB penetration through a damaged cell membrane)
60 4D).
(Figure
3.3. 40
Antiviral activity against poliovirus type 1 in Hep-2
cells
A
Interferon
α-2a showed significant antiviral activity against
20
poliovirus type 1 in both preinfection and postinfection

Cell survival (%) .

were removed, and the cell monolayers were rinsed with
DPBS and infected with a suspension of poliovirus type
1 (100 TCID50/mL). After a 7-day incubation, the plates
were subjected to the UptiBlue assay.
2.7.2. Postinfection treatment assay
Hep-2 cell monolayers were incubated with a poliovirus
type 1 suspension (100 TCID50/mL) for 90 min at 37 °C
and 5% CO2. After incubation, the viral suspension was
removed and the cell monolayers were rinsed with DPBS.
Compounds 1, 2, and 3 and the corresponding controls
were applied to Hep-2 cell monolayers. After a 7-day
incubation, the plates were subjected to the UptiBlue assay.
2.8. Statistical analysis
The validity of the assay and results of poliovirus type
1 standardization were statistically interpreted using
CombiStats (EDQM, 2009) software for statistical analysis
of biological dilution assays. Calculations were done
according to Chapter 5.3 of the European Pharmacopoeia
(Council of Europe, 2013). Results obtained in the
cytotoxicity and antiviral activity assays were expressed as
mean values obtained from three independent experiments
performed at least in triplicate. The data are presented as
mean values ± standard error (SE). Student’s t-test was
used to evaluate the difference between the test data and
control. P < 0.05 was considered statistically significant.
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Figure 2. Cytotoxic effect of A) cisplatin, carboplatin, and oxaliplatin, and B) test compounds 1, 2, and 3 in A549 cells.
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Figure 3. Representative photomicrographs showing the morphological changes of A549 cells after treatment
with ligand, observed through an inverted phase contrast microscope (A, C, E: 200× magnification; B, D, F:
400× magnification). A, B – control A549 cells; C, D – 24 h of treatment; E, F – 48 of h treatment. Arrows
point to (1) cell rounding, (2) membrane blebbing, (3) cell shrinkage, (4) cell fragmentation, (5) nuclear
fragmentation, (6) apoptotic bodies, and (7) echinoid spikes.

treatments (Figure 5). In the preinfection treatment with
interferon α-2a, the EC50 value was 32.5 ± 3.7 IU/mL,
with a therapeutic index (TI) of greater than 30.8. In the
postinfection treatment with interferon α-2a, the EC50
value was 51 ± 1.16 IU/mL, and the TI was greater than
19.6. The Pd(II) complex did not display an antiviral effect
in either the preinfection or postinfection treatments, as the
CPE remained at 100% for all of the tested concentrations
(data not shown).
3.3.1. Preinfection treatment assay
The results of the preinfection treatment with the ligand
and Pt(II) complex are presented in Figure 6. For the

ligand, significant inhibition of the CPE was detected at
2.38 µM and above, with the highest effect observed at
19 µM (24.42 ± 1.49% of CPE reduction). For the Pt(II)
complex, a significant inhibition of the CPE was detected
at 4.25 µM and above, with the highest effect observed
at 17 µM (11.14 ± 1.50% of CPE reduction). From these
results it is evident that in the preinfection treatment the
ligand showed a higher antiviral potential than the Pt(II)
complex.
3.3.2. Postinfection treatment assay
The results of the postinfection treatment are presented in
Figure 7. For the ligand, a significant inhibition of the CPE
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Figure 4. Representative photomicrographs showing the morphological changes of AO/EB-stained A549 cells after
treatment with ligand, observed through a fluorescence microscope (400× magnification). A, B – control A549 cells; C,
D – 48 h of treatment. Arrows point to (1) live nonapoptotic cells, (2) membrane blebbing, (3) chromatin condensation,
(4) early apoptotic cell, (5) late apoptotic cell, and (6) cell fragmentation.

Interferon alpha-2a
Postinfection treatment assay

.
Reduction of CPE (%)

*

80

*

60
*

40
20

*

*

*

*

1

*

*

*

10
100
Concentrations (IU/mL)

1000

Figure 5. Reduction of poliovirus type 1-induced CPE after
treatment with interferon α-2a (*: P < 0.05).
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Figure 6. Reduction of poliovirus type 1-induced CPE in the
preinfection treatment with compounds 1 and 3 (*: P < 0.05).
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Figure 7. Reduction of poliovirus type 1-induced CPE in the
postinfection treatment with compounds 1 and 3 (*: P < 0.05).

was detected at concentrations of 2.38 µM and higher, with
the highest effect observed at 19 µM (11.8 ± 1.13% of CPE
reduction). For the Pt(II) complex, a significant inhibition
of the CPE was measured at concentrations of 2.13 µM and
above, with the highest effect observed at 17 µM (30.52
± 3.12% of CPE reduction). From these results it is clear
that in the postinfection treatment the Pt(II) complex
possessed a higher antiviral potential than the ligand.
4. Discussion
The development of biologically active agents that exploit
differences between cancerous and normal cells, that
possess a higher specificity for cancer cells, and that
cause less damage to normal cells remains the ultimate
objective in antineoplastic drug development (Adams,
2001). The cytotoxic activity of novel Pd(II) and Pt(II)
complexes with the 2-(diphenylphosphino)benzaldehyde
1-adamantoylhydrazone ligand was previously analyzed in
human larynx carcinoma cells (Hep-2) and healthy human
lung fibroblast cells (MRC-5) (Đorđević et al., 2014).
Previous results in Hep-2 cells showed that the Pt(II)
complex and the ligand itself have cytotoxic activities
within the range of oxaliplatin’s activity. The MRC-5 cell
line manifested high tolerance to the ligand and its metal
complexes. These novel compounds are characterized with
selective cytotoxic activity to cancerous Hep-2 cells in
comparison to healthy MRC-5 cells.
The results obtained from the examination of
cytotoxicity in A549 cells revealed that the ligand displays
a dose-dependent cytotoxic activity that is 4 times weaker
than that of cisplatin and oxaliplatin, but markedly higher
than that of carboplatin. Comparison of the cytotoxicity
results of A549 cells and the results obtained in our
previous experiments in healthy lung MRC-5 cells (IC50 =

114.07 ± 5.11 µM) (Đorđević et al., 2014) revealed that the
ligand does not display specificity to A549 cells. In contrast
to the ligand, neither the Pt(II) nor the Pd(II) complex
induced cell death in A549 cells at the tested range of
concentrations. The cytotoxicity results indicate that the
introduction of the metal into this ligand structure does
not increase the agent’s cytotoxicity in the A549 cell line.
Development of palladium(II)-containing compounds
is based on the similarity of the coordination chemistry
of Pt(II) and Pd(II) complexes. However, most of
the palladium complexes are characterized by lower
cytotoxicity in comparison to their platinum analogs,
probably due to their faster hydrolysis, which results
in highly reactive species that cannot reach their
pharmacological targets (Abu-Surrah et al., 2008). In
addition to the physicochemical properties of these
compounds, the absence of cytotoxic activity of Pt(II) and
Pd(II) complexes (compounds 2 and 3, respectively) in
A549 cells could be related to the high resistance potential
of these cells. This is mediated by mechanisms involved in
resistance development, such as reduced cellular uptake,
increased efflux, and increased DNA repair (Rabik and
Dolan, 2007).
Morphological evaluation of A549 cells that were
treated with the ligand revealed the presence of typical signs
of early and late apoptosis, such as membrane blebbing,
chromatin condensation, and formation of apoptotic
bodies (Vejselova and Kutlu, 2015). Thus, the ligand can
be considered an apoptosis-inducing agent. Complexes
comprising Pt(II) and Pd(II) and the condensation
product of 2-(diphenylphosphino)benzaldehyde (dpba)
hydrazone and semioxamazide display strong cytotoxicity
to cisplatin-resistant osteosarcoma U2-OS/Pt cells and
induce apoptosis in HeLa cells without causing significant
perturbations of the cell cycle (Malešević et al., 2006).
In view of the considerable similarities in the chemical
structures of other dpba hydrazones and the ligand
(compound 1), they probably exert their effects through
the same mechanisms of action.
Assessment of the antiviral effect under different
experimental conditions provides information as to the
intracellular action of an agent at specific steps in the
virus life cycle (Enan et al., 2012). Investigation of the
antiviral activity of the Pd(II) complex revealed that this
compound does not possess any antiviral activity against
poliovirus type 1 at the level of viral adsorption and viral
replication, as there was no observable reduction of CPE at
any of the applied concentrations. Treatment of cells with
the ligand and the Pt(II) complex prior to poliovirus type
1 infection resulted in some antiviral activity. The ligand
expressed better antiviral activity than the Pt(II) complex.
According to Šmidling et al. (2008) this probably resulted
from the blockage of virus receptor binding sites on the
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cell surface and decreased viral adsorption. Treatment of
cells with the ligand and Pt(II) complex after infection
with the poliovirus revealed a greater antiviral potential of
the Pt(II) complex and its ability to reduce viral replication
in comparison to the ligand. The decrease of viral activity
induced by the Pt(II) complex was achieved by inhibition
of viral replication.
Although we obtained significant inhibition of
CPE with the ligand and Pt(II) complex, 50% of viral
inhibition (the threshold antiviral activity recommended
by the FDA) was not obtained. Therefore, relative to this
recommendation, the ligand and Pt(II) complexes have
weak antiviral activity.
Of
the
examined
compounds,
ligand
2-(diphenylphosphino) benzaldehyde 1-adamantoylhydrazone exhibits cytotoxic activity and induces

morphological changes associated with apoptosis. Thus,
it should be viewed as a potential anticancer agent. The
ligand and the Pt(II) complex caused viral inhibition and
should be considered for further investigation of antiviral
activity.
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